The stock of enGene Holdings Inc (NASDAQ: ENGN) has increased by 9.03 when compared to last closing price of 2.99.Despite this, the company has seen a gain of 0.31% in its stock price over the last five trading days. businesswire.com reported 2025-06-25 that BOSTON & MONTREAL–(BUSINESS WIRE)–enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company’s lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive,.
Is It Worth Investing in enGene Holdings Inc (NASDAQ: ENGN) Right Now?
Additionally, the 36-month beta value for ENGN is -0.44. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENGN is 21.89M and currently, short sellers hold a 0.18% ratio of that float. The average trading volume of ENGN on June 26, 2025 was 74.19K shares.
ENGN’s Market Performance
ENGN stock saw a decrease of 0.31% in the past week, with a monthly decline of -23.11% and a quarterly a decrease of -33.87%. The volatility ratio for the week is 6.12%, and the volatility levels for the last 30 days are 4.89% for enGene Holdings Inc (ENGN). The simple moving average for the past 20 days is -6.63% for ENGN’s stock, with a -45.83% simple moving average for the past 200 days.
Analysts’ Opinion of ENGN
Many brokerage firms have already submitted their reports for ENGN stocks, with Piper Sandler repeating the rating for ENGN by listing it as a “Overweight.” The predicted price for ENGN in the upcoming period, according to Piper Sandler is $26 based on the research report published on February 18, 2025 of the current year 2025.
UBS, on the other hand, stated in their research note that they expect to see ENGN reach a price target of $7, previously predicting the price at $34. The rating they have provided for ENGN stocks is “Neutral” according to the report published on February 14th, 2025.
H.C. Wainwright gave a rating of “Buy” to ENGN, setting the target price at $25 in the report published on December 23rd of the previous year.
ENGN Trading at -11.00% from the 50-Day Moving Average
After a stumble in the market that brought ENGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.36% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENGN starting from Forbion Growth Opportunities F, who purchase 561,797 shares at the price of $8.90 back on Oct 30 ’24. After this action, Forbion Growth Opportunities F now owns 3,032,430 shares of enGene Holdings Inc, valued at $4,999,993 using the latest closing price.
Forbion Growth Opportunities F, the 10% Owner of enGene Holdings Inc, purchase 341,332 shares at $6.34 during a trade that took place back on Sep 30 ’24, which means that Forbion Growth Opportunities F is holding 2,400,791 shares at $2,163,362 based on the most recent closing price.
Stock Fundamentals for ENGN
The total capital return value is set at -0.14. Equity return is now at value -33.97, with -29.57 for asset returns.
Based on enGene Holdings Inc (ENGN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -42.67. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11.26.
Currently, EBITDA for the company is 62.3 million with net debt to EBITDA at 2.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.66.
Conclusion
In conclusion, enGene Holdings Inc (ENGN) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
